TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05224089
Drug: Bupivacaine HCL
Normalized name: bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80mL 0.25% bupivacaine (200mg) + 300mcg (0.3mL) epinephrine + 5mg (0.5mL) preservative free dexamethasone + 20mL NS= 100mL
Study: NCT05678348
Drug: Pyrimethamine
Normalized name: Pyrimethamine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be instructed to take their dose at approximately the same time each day.
Study: NCT06794229
Drug: Zanzalintinib
Normalized name: Zanzalintinib
DrugBank: Zanzalintinib (DB17525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zanzalintinib 100mg orally (PO) once daily for 12 weeks up (all subjects) and up to 48 weeks from Cycle 1 Day 1 (Cohort B1)
Study: NCT06794229
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab will be administered at either 240mg IV every 2 weeks or 480mg IV 4 every weeks for 12 weeks (all subjects) and up to 48 weeks from Cycle 1 Day 1 (Cohort B1).
Study: NCT05339256
Drug: Buprenorphine SL
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Up to 24 mg per day
Study: NCT06045754
Drug: Vedolizumab
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vedolizumab intravenous infusion.
Study: NCT06045754
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab subcutaneous injection.
Study: NCT06045754
Drug: Ustekinumab
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ustekinumab intravenous infusion.
Study: NCT06045754
Drug: Ustekinumab
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ustekinumab subcutaneous injection.
Study: NCT06459180
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV infusion
Study: NCT06459180
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion
Study: NCT06459180
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion
Study: NCT06459180
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion
Study: NCT06459180
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion
Study: NCT03980769
Drug: Thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT03980769
Drug: Treosulfan
Normalized name: TREOSULFAN
DrugBank: Treosulfan (DB11678)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Given IV
Study: NCT03980769
Drug: Fludarabine Phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT06556368
Drug: Tarcocimab tedromer
Normalized name: Tarcocimab tedromer
DrugBank: Tarcocimab tedromer (DB18937)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection
Study: NCT06556368
Drug: Tabirafusp tedromer
Normalized name: Tabirafusp tedromer
DrugBank: Tabirafusp tedromer (DB19340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection
Study: NCT06556368
Drug: Aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal injection
Study: NCT05173597
Drug: Follitropin delta
Normalized name: follitropin delta
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: REKOVELLE® (follitropin delta), solution for injection - delivered with an injection pen, ATC code G03GA10, is a recombinant human FSH approved for the controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies such as an in vitro fertilisation or intracytoplasmic sperm injection cycle.
Study: NCT06221670
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a prospective, open, single-center, single-arm phase II clinical study with no driver mutations identified in the central laboratory，to evaluate the efficacy and safety of adjuvant Toripalimab therapy in completely resected stage IA2-IB non-squamous NSCLC with high-risk factors.
Study: NCT06096337
Drug: Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone
DrugBank: Dofetilide (DB00204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti-Arrhythmic Drugs (AADs) including, Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone will be prescribed and monitored in accordance with local clinical practice and already established guideline-directed therapy for patients with persistent atrial fibrillation (AF).
Study: NCT04671667
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04671667
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT05521087
Drug: JNJ-75276617
Normalized name: JNJ-75276617
DrugBank: JNJ-75276617 (DB17574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-75276617 will be administered orally.
Study: NCT05521087
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine chemotherapy will be administered as intravenous (IV) infusion for participants with AML.
Study: NCT05521087
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytarabine chemotherapy will be administered as IV infusion for participants with AML.
Study: NCT05521087
Drug: Intrathecal Chemotherapy
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal chemotherapy will be administered as IV infusion for participants with AML or B-cell ALL.
Study: NCT05521087
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone chemotherapy will be administered as IV infusion for participants with B-cell ALL.
Study: NCT05521087
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vincristine chemotherapy will be administered as IV infusion for participants with B-cell ALL.
Study: NCT05521087
Drug: Pegaspargase
Normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegaspargase chemotherapy will be administered as IV infusion for participants with B-cell ALL.
Study: NCT06643390
Drug: MK-2225
Normalized name: MK-2225
DrugBank: MK-2225 (DB18240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration
Study: NCT06083857
Drug: Amivantamab
Normalized name: amivantamab
DrugBank: Amivantamab (DB16695)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given by IV (vein)
Study: NCT06083857
Drug: Tepotinib
Normalized name: Tepotinib
DrugBank: Tepotinib (DB15133)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by PO
Study: NCT06378528
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 Intravenous ketamine administrations (0.5mg/kg, not to exceed 40mg dose) immediately prior to a psychotherapy session over the span of 6 weeks
Study: NCT06517563
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: FXa Inhibitor
Study: NCT06517563
Drug: Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Molecular Weight Heparin
Study: NCT05268497
Drug: Esketamine
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Esketamine will be self-administered as nasal spray.
Study: NCT04994717
Drug: Blinatumomab
Normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Continuous intravenous (cIV) infusion
Study: NCT06280716
Drug: Lebrikizumab
Normalized name: Lebrikizumab
DrugBank: Lebrikizumab (DB11914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT05996471
Drug: Cabotegravir
Normalized name: cabotegravir
DrugBank: Cabotegravir (DB11751)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabotegravir will be administered.
Study: NCT06773910
Drug: BMS-986489
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS-986489 (fixed dose combination of atigotatug + nivolumab) will be administered as an intravenous infusion to be given once every 4 weeks for up to 2 years.
Study: NCT06773910
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab will be administered as a fixed dose intravenous infusion to be given once every 4 weeks for up to 2 years.
Study: NCT06049017
Drug: JNJ-77242113
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-77242113 tablet will be administered orally.
Study: NCT06801223
Drug: Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours)
DrugBank: Sulbactam (DB09324)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg/kg SUL and 25mg/kg DUR
Study: NCT06801223
Drug: Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours)
DrugBank: Sulbactam (DB09324)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg/kg SUL and 20mg/kg DUR
Study: NCT06801223
Drug: Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours)
DrugBank: Sulbactam (DB09324)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg/kg SUL and 25mg/kg DUR
Study: NCT05702034
Drug: Milvexian
Normalized name: Milvexian
DrugBank: Milvexian (DB16233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milvexian will be administered orally.
Study: NCT06408935
Drug: Guselkumab
Normalized name: Guselkumab
DrugBank: Guselkumab (DB11834)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Guselkumab will be administered IV and SC.
Study: NCT06260163
Drug: Guselkumab Subcutaneous
DrugBank: Guselkumab (DB11834)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Guselkumab will be administered subcutaneously.
Study: NCT06260163
Drug: Guselkumab Intravenous
DrugBank: Guselkumab (DB11834)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Guselkumab will be administered intravenously.
Study: NCT06120075
Drug: AB801
Normalized name: Abacavir
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT06120075
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT05683834
Drug: Matrix-M1 Adjuvant
Normalized name: Matrix-M1 Adjuvant
DrugBank: Matrix-M (DB16369)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matrix-M1 is composed of 2 types of 40 nm-sized particles each with a different saponin fraction (fraction A and fraction B) combined with cholesterol and phospholipid.
Study: NCT05683834
Drug: EBV gp350-Ferritin Vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The EBV gp350-Ferritin vaccine is composed of Helicobacter pylori non-heme ferritin fused to EBV gp350 which self-assembles to form a nanoparticle. The vaccine is supplied in single-use vials at a concentration of 250 micrograms/mL in 1.7 mM KH2PO4, 5 mM Na2HPO4, 150 mM NaCl, 5% sucrose, pH 7.4 (diluent).
Study: NCT06316830
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine in a highly effective treatment for opioid use disorder (OUD). Buprenorphine dose guidelines for OUD treatment were determined by clinical trials conducted in populations with a history of heroin use. However, fentanyl is changing the calculation of treatment, and optimal buprenorphine dosing for people who use fentanyl is unknown.
Study: NCT06436768
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After the last dose of rocuronium, at reappearance of T2, a dose of 2.0 mg/kg sugammadex was administered.~Dose will be according to participant actual body weight.
Study: NCT06436768
Drug: Neostigmine
Normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After the last dose of rocuronium, at reappearance of T2, a dose of 50 ug/kg neostigmine (up to 5 mg maximum dose) plus atropine 0.02 mg/kg (up to 2 mg maximum dose) was administered.~Dose will be according to participant actual body weight.
Study: NCT05645536
Drug: TOL2506
DrugBank: TOL2 (DB17918)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide Acetate for injectable suspension, 30 mg. Subcutaneous injection every 3 months
Study: NCT05645536
Drug: Tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg once daily or 10 mg 2 times daily - either tablet of solution
Study: NCT05645536
Drug: Letrozole tablets
Normalized name: Letrozole Tablets
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 2.5 mg tablet taken orally once daily
Study: NCT05645536
Drug: Anastrozole Tablets
Normalized name: Anastrozole Tablets
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 1 mg tablet taken orally once daily
Study: NCT05645536
Drug: Exemestane Tablets
Normalized name: Exemestane Tablets
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 25 mg tablet taken orally once daily
Study: NCT05839600
Drug: BI 1821736
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for infusion
Study: NCT05672134
Drug: Geranylgeranylacetone (GGA)
Normalized name: geranylgeranylacetone
DrugBank: Teprenone (DB15955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13 weeks of treatment with GGA/placebo orally, followed by a wash-out period of 6 weeks, then reversal of the treatment arms.
Study: NCT06635135
Drug: Aticaprant
Normalized name: Aticaprant
DrugBank: Aticaprant (DB12341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aticaprant will be administered orally.
Study: NCT04531878
Drug: 4-Phenylbutyrate
Normalized name: 4-phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-phenylbutyrate therapy will be started at a daily dose of 200 mg kg/d divided in 2 oral doses of sodium phenylbutyrate (AMMONAPS, Swedish Orphan Inter AB). In order to get the best effect, the dose will be increased up to a maximum of 500 mg kg/d.
Study: NCT06799741
Drug: AV-1 100 mg
Normalized name: AVS-100
DrugBank: AV-101 (DB12878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: human monoclonal antibody (mAb) intravenous solution~or
Study: NCT06799741
Drug: AV-1 300 mg
Normalized name: AVS-100
DrugBank: AV-101 (DB12878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: human monoclonal antibody (mAb) intravenous solution~or
Study: NCT06799741
Drug: AV-1 900 mg
Normalized name: AVS-100
DrugBank: AV-101 (DB12878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: human monoclonal antibody (mAb) intravenous solution~or
Study: NCT05851898
Drug: Duloxetine 30 mg
Normalized name: duloxetine 30 MG
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duloxetine 30mg daily prescribed at discharge
Study: NCT05361382
Drug: 18F-Flortaucipir radiopharmaceutical
Normalized name: Flortaucipir (18F)
DrugBank: Flortaucipir (DB15033)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flortaucipir is a PET radiopharmaceutical that binds to tau neurofibrillary tangles. Participants will receive a bolus intravenous injection of approximately 10 millicuries of the radiopharmaceutical.
Study: NCT05361382
Drug: Amyloid-β radiopharmaceutical (11C-PiB or 18F-Florbetaben or 18F-NAV-4694 or 18F-Florbetapir)
Normalized name: .beta.-amyloid protein-(1-6)-peptidylglycylglycyl-L-cysteine-3-(2,5-dioxo-2,5-dihydro-1H-pyrrole-1-yl)-n-(6-((2,5-dioxopyrrolidin-1-yl)oxy)-6-oxohexyl)propanamide-alanine
DrugBank: Amyl acetate (DB15927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The clinical sites will use either PiB, Florbetaben, Florbetapir, or NAV-4694 as the amyloid-β PET radiopharmaceutical. The amyloid-β PET radiopharmaceutical binds to amyloid-β plaques.~Participants will receive a bolus intravenous injection of approximately 15 millicuries of the PiB radiopharmaceutical.~Participants will receive a bolus intravenous injection of approximately 8 millicuries of the Florbetaben or NAV-4694 radiopharmaceutical.~Participants will receive a bolus intravenous injection of approximately 10 millicuries of the Florbetapir radiopharmaceutical.
Study: NCT05379166
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT05379166
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT05762471
Drug: GSBR-1290
Normalized name: GSBR-1290
DrugBank: GSBR-1290 (DB18551)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive GSBR-1290 or matching Placebo
Study: NCT04969315
Drug: TT-10
Normalized name: CTT-1057
DrugBank: CTT-1057 (DB14965)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TT-10 orally administered BID
Study: NCT04969315
Drug: TT-4
Normalized name: TT 173
DrugBank: TT 173 (DB17717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TT-4 is orally administered QD
Study: NCT04616677
Drug: JNJ-42847922
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-42847922 tablet will be administered orally.
Study: NCT06561386
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose on specified days
Study: NCT06561386
Drug: Relatlimab
Normalized name: Relatlimab
DrugBank: Relatlimab (DB14851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06561386
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose on specified days
Study: NCT06561386
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT06561386
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT06561386
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05930002
Drug: Ivermectin Tablets
Normalized name: Ivermectin Tablets
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral tablets (0.2 mg/kg/day) single dose on an empty stomach for three successive days.
Study: NCT05930002
Drug: Colchicine 0.5 MG
Normalized name: colchicine 0.5 MG
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5mg tablets (3times/day after meal for 3 days then twice daily for 4 days)
Study: NCT05042362
Drug: Elinzanetant (BAY3427080)
Normalized name: Elinzanetant
DrugBank: Elinzanetant (DB18968)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg elinzanetant orally once daily
Study: NCT04313036
Drug: Defibrotide
Normalized name: Defibrotide
DrugBank: Defibrotide (DB04932)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 25 mg/kg/day at 4 divided doses of 6.25 mg/kg, 2-h infusion given for 5 days, if not in CR treatment continued for \>/= 21 days or per discretion of enrolling physician.
Study: NCT05403138
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction Phase: (8mg/kg) via intravenous (IV) evey 2 weeks for two cycles. Maintenance Phase: (4mg/kg) IV every 4 weeks.
Study: NCT04316676
Drug: Regadenoson
Normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacological stress testing for the CT-MPI scan will be performed with a single injection of 0.4 mg of regadenoson (Lexiscan).
Study: NCT00284999
Drug: Soothe
Normalized name: Soothe
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00284999
Drug: Refresh Tears
Normalized name: Refresh Tears
DrugBank: Carboxymethylcellulose (DB11059)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05906303
Drug: Caffeine and Sodium Benzoate Injection
Normalized name: Caffeine and Sodium Benzoate Injection
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Provide caffeine to shorten second stage of labor and augment pushing efforts
Study: NCT06283836
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: monitored anesthesia care (sedation)
Study: NCT05610163
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05610163
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05610163
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06480500
Drug: Ketamine hydrochloride
Normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 55 patients will receive ketamine hydrochloride, over six infusions, flexibly dosed between 0.5 mg/kg to 0.85 mg/kg.
Study: NCT05989165
Drug: Minoxidil 5% Topical Solution
Normalized name: Minoxidil 5% Topical solution
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient will be given minoxidil 5% topical solution, twice a day for 12 weeks
Study: NCT06332950
Drug: Adebrelimab, Irinotecan Liposome (II)
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adebrelimab:1200 mg, IV, D1, Q3W~Irinotecan Liposome (II): RP2D, IV, D1, Q3W~Escalating doses to determine recommended phase 2 dose (RP2D) of Irinotecan Liposome (II).~Participants will receive Adebrelimab (1200 mg, IV, D1, Q3W) plus the RP2D of Irinotecan Liposome (II).
Study: NCT06332950
Drug: Adebrelimab, Irinotecan Liposome (II), Famitinib
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adebrelimab:1200 mg, IV, D1, Q3W~Irinotecan Liposome (II): RP2D, IV, D1, Q3W~Famitinib: RP2D, QO, QD~Escalating doses to determine recommended phase 2 dose (RP2D) of Famitinib.~Participants will receive Adebrelimab (1200 mg, IV, D1, Q3W) plus the RP2D of Irinotecan Liposome (II) and Famitinib.